[go: up one dir, main page]

AR098909A1 - Compuesto heterocíclico - Google Patents

Compuesto heterocíclico

Info

Publication number
AR098909A1
AR098909A1 ARP140104851A ARP140104851A AR098909A1 AR 098909 A1 AR098909 A1 AR 098909A1 AR P140104851 A ARP140104851 A AR P140104851A AR P140104851 A ARP140104851 A AR P140104851A AR 098909 A1 AR098909 A1 AR 098909A1
Authority
AR
Argentina
Prior art keywords
group
optionally substituted
ring
alkyl
optionally
Prior art date
Application number
ARP140104851A
Other languages
English (en)
Inventor
Yamamoto Satoshi
Shirai Junya
Fukumoto Shoji
Watanabe Hiroyuki
Oda Tsuneo
Tokuhara Hidekazu
Tomata Yoshihide
Ishii Naoki
Tawada Michiko
Kouno Mitsunori
Ochida Atsuko
Imada Takashi
Fukase Yoshiyuki
Yukawa Tomoya
Original Assignee
Takeda Pharmaceuticals Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Company Ltd filed Critical Takeda Pharmaceuticals Company Ltd
Publication of AR098909A1 publication Critical patent/AR098909A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente solicitud se refiere a un compuesto o una sal del mismo que tiene una acción inhibidora de RORᵍt donde ROR es un receptor retinoide. Reivindicación 1: Un compuesto representado por la fórmula [1], caracterizado porque el anillo A es un anillo además opcionalmente sustituido aromático de 6 miembros; R¹ es (1) un grupo representado por la fórmula: -Q(R¹ᵃ)(R¹ᵇ)(R¹ᶜ) en donde Q es un átomo de carbono, un átomo de silicio o un átomo de germanio, y R¹ᵃ, R¹ᵇ y R¹ᶜ son cada uno independientemente un sustituyente, o R¹ᵃ y R¹ᵇ en combinación opcionalmente forman, junto con el Q adyacente, un anillo además opcionalmente sustituido, y R¹ᶜ está unido opcionalmente a un sustituyente para el Anillo A para formar un anillo además opcionalmente sustituido, (2) un grupo neo-pentilo, o (3) un grupo trimetilsililmetilo; R¹¹ es -CR¹²R¹²-R¹², -C(=O)-R⁴ o -SO₂-R¹³; R¹², R¹² y R¹² son cada uno independientemente un átomo de hidrógeno, un átomo de halógeno, un grupo ciano, un grupo nitro, un grupo alquilo C₁₋₆ opcionalmente sustituido, un grupo alquenilo C₂₋₆ opcionalmente sustituido, un grupo alquinilo C₂₋₆ opcionalmente sustituido, un grupo heterocíclico opcionalmente sustituido o un. grupo tiocarbamoilo opcionalmente sustituido; R⁴ es un grupo alquilo C₁₋₆ opcionalmente sustituido, un grupo alquenilo C₂₋₆ opcionalmente sustituido, un grupo alquinilo C₂₋₆ opcionalmente sustituido, un grupo heterocíclico opcionalmente sustituido, un grupo acilo, un grupo amino opcionalmente sustituido, un grupo carbamoilo opcionalmente sustituido, un grupo tiocarbamoilo opcionalmente sustituido, un grupo sulfamoilo opcionalmente sustituido, un grupo hidroxi opcionalmente sustituido, un grupo sulfanilo (SH) opcionalmente sustituido o un grupo sililo opcionalmente sustituido, en donde el grupo alquilo C₁₋₆, ₑₗ ᵍʳᵘₚₒ ₐₗqᵘₑₙⁱₗₒ C₂₋₆ ʸ ₑₗ ᵍʳᵘₚₒ ₐₗqᵘⁱₙⁱₗₒ C₂₋₆, el grupo alquilo C₁₋₆ opcionalmente sustituido, el grupo alquenilo C₂₋₆ opcionalmente sustituido y el grupo alquinilo C₂₋₆ opcionalmente sustituido para R⁴ están cada uno opcionalmente sustituidos por 1 a 5 sustituyentes seleccionados de (1) un átomo de halógeno, (2) un grupo nitro, (3) un grupo ciano, (4) un grupo oxo, (5) un grupo hidroxi, (6) un grupo alcoxi C₁₋₆ opcionalmente sustituido por sustituyente/s seleccionado/s de un átomo de halógeno y un grupo carboxi, (7) un grupo ariloxi C₆₋₁₄, (8) un grupo aralquiloxi C₇₋₁₆, (9) un grupo heterocicliloxi aromático de 5 a 14 miembros, (10) un grupo heterocicliloxi no aromático de 3 a 14 miembros, (11) un grupo alquilo C₁₋₆-carboniloxi, (12) un grupo aril C₆₋₁₄-carboniloxi, (13) un grupo alcoxi C₁₋₆-carboniloxi, (14) un grupo mono- o di-alquil C₁₋₆-carbamoiloxi, (15) un grupo aril C₆₋₁₄-carbamoiloxi, (16) un grupo heterociclilcarboniloxi aromático de 5 a 14 miembros, (17) un grupo heterociclilcarboniloxi no aromático de 3 a 14 miembros, (18) un grupo alquilsulfoniloxi C₁₋₆ opcionalmente halogenado, (19) un grupo arilsulfoniloxi C₆₋₁₄ opcionalmente sustituido por grupo/s alquilo C₁₋₆, (20) un grupo alquiltio C₁₋₆ opcionalmente halogenado, (21) un grupo heterocíclico aromático de 5 a 14 miembros opcionalmente sustituido por sustituyente/s seleccionado/s de un grupo hidroxi, un grupo alquilo C₁₋₆, un grupo alcoxi C₁₋₆ y un grupo carboxi, (22) un grupo heterocíclico no aromático de 3 a 14 miembros opcionalmente sustituido por sustituyente/s seleccionado/s de un grupo oxo y un grupo alquilo C₁₋₆, (23) un grupo formilo, (24) un grupo carboxi, (25) un grupo alquil C₁₋₆-carbonilo opcionalmente halogenado, (26) un grupo aril C₆₋₁₄-carbonilo, (27) un grupo heterociclilcarbonilo aromático de 5 a 14 miembros, (28) un grupo heterociclilcarbonilo no aromático de 3 a 14 miembros, (29) un grupo alcoxi C₁₋₆-carbonilo, (30) un grupo ariloxi C₆₋₁₄-carbonilo, (31) un grupo aralquiloxi C₇₋₁₆-carbonilo, (32) un grupo carbamoilo, (33) un grupo tiocarbamoilo, (34) un grupo mono- o di-alquilo C₁₋₆-carbamoilo, (35) un grupo aril C₆₋₁₄-carbamoilo, (36) un grupo heterociclilcarbamoilo aromático de 5 a 14 miembros, (37) un grupo heterociclilcarbamoilo no aromático de 3 a 14 miembros, (38) un grupo alquilsulfonilo C₁₋₆ opcionalmente halogenado, (39) un grupo arilsulfonilo C₆₋₁₄, (40) un grupo heterociclilsulfonilo aromático de 5 a 14 miembros, (41) un grupo alquilsulfinilo C₁₋₆ opcionalmente halogenado, (42) un grupo arilsulfinilo C₆₋₁₄, (43) un grupo heterociclilsulfinilo aromático de 5 a 14 miembros, (44) un grupo amino, (45) un grupo mono- o di-alquilamino C₁₋₆ (el alquilo C₁₋₆ es opcionalmente sustituido por grupo/s carboxi), (46) un grupo mono- o di-arilamino C₆₋₁₄, (47) un grupo heterociclilamino aromático de 5 a 14 miembros, (48) un grupo aralquilamino C₇₋₁₆, (49) un grupo fromilamino, (50) un grupo alquil C₁₋₆-carbonilamino, (51) un grupo (alquil C₁₋₆)(alquil C₁₋₆-carbonil)amino, (52) un grupo aril C₆₋₁₄-carbonilamino, (53) un grupo alcoxi C₁₋₆-carbonilamino, (54) un grupo aralquiloxi C₇₋₁₆-carbonilamino, (55) un grupo alquilsulfonilamino C₁₋₆, (56) un grupo arilsulfonilamino C₆₋₁₄ opcionalmente sustituido por grupo/s alquilo C₁₋₆, (57) un grupo alquilo C₁₋₆ opcionalmente halogenado, (58) un grupo alquenilo C₂₋₆ y (59) un grupo alquinilo C₂₋₆; R¹³ es un sustituyente; el anillo B es un anillo de benceno, un anillo de piridina o un anillo de dihidropiridina, cada uno de los cuales además está opcionalmente sustituido; la estructura parcial representada por la fórmula [2] es CR⁵ᵃ=CR⁶, CR⁵ᵇ=N o C(=O)-NR⁷; R⁵ᵃ y R⁵ᵇ son cada uno independientemente un grupo alquilo opcionalmente sustituido, un grupo alcoxi opcionalmente sustituido, un grupo alquilsulfonilo opcionalmente sustituido, un grupo ciano, un grupo amino cíclico opcionalmente sustituido o un grupo oxetan-3-iloxi; y R⁶ y R⁷ son cada uno independientemente un átomo de hidrógeno o un sustituyente; o el sustituyente que el anillo B opcionalmente además tiene y R⁵ᵃ o R⁵ᵇ en combinación opcionalmente forman el anillo D, en donde el anillo D es un heterociclo que contiene oxigeno de 5 ó 6 miembros que contiene 1 a 2 átomos de oxígeno como heteroátomos además de los átomos de carbono, y está fusionado en la posición formadora del anillo, o R⁵ᵃ y R⁶ en combinación opcionalmente forman el anillo D, en donde el anillo D es un heterociclo que contiene oxígeno de 5 ó 6 miembros que contiene 1 a 2 átomos de oxígeno como heteroátomos además de los átomos de carbono, y está fusionado en la posición formadora del anillo; Y es un grupo metileno opcionalmente sustituido o un átomo de oxígeno; y W es un grupo alquileno C₁₋₂ opcionalmente sustituido; o una sal del mismo.
ARP140104851A 2013-07-03 2014-12-22 Compuesto heterocíclico AR098909A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013140210 2013-07-03
PCT/JP2014/067650 WO2015002231A1 (ja) 2013-07-03 2014-07-02 複素環化合物

Publications (1)

Publication Number Publication Date
AR098909A1 true AR098909A1 (es) 2016-06-22

Family

ID=52143803

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140104851A AR098909A1 (es) 2013-07-03 2014-12-22 Compuesto heterocíclico

Country Status (6)

Country Link
US (2) US10053468B2 (es)
EP (1) EP3018126A4 (es)
JP (1) JP6427491B2 (es)
AR (1) AR098909A1 (es)
TW (1) TW201602105A (es)
WO (1) WO2015002231A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014142255A1 (ja) 2013-03-14 2014-09-18 武田薬品工業株式会社 複素環化合物
JP6427491B2 (ja) 2013-07-03 2018-11-21 武田薬品工業株式会社 複素環化合物
JP6411342B2 (ja) 2013-07-03 2018-10-24 武田薬品工業株式会社 アミド化合物
CN106795118B (zh) 2014-07-01 2019-10-08 武田药品工业株式会社 杂环化合物和它们作为类视黄醇相关的孤儿受体(ror)gamma-t抑制剂的用途
EP3192791A4 (en) 2014-09-11 2018-03-28 Takeda Pharmaceutical Company Limited Heterocyclic compound
TN2018000188A1 (en) 2015-12-15 2019-10-04 Astrazeneca Ab Isoindole compounds
AU2016377658B2 (en) 2015-12-22 2022-09-29 Endosome Therapeutics, Inc. Tripartite modulators of endosomal G protein-coupled receptors
EP3638661A1 (en) 2017-06-14 2020-04-22 Astrazeneca AB 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators
CN108191633A (zh) * 2018-01-23 2018-06-22 辽宁东科药业有限公司 一种合成对甲氧基苯乙酸的方法
AU2020378005A1 (en) 2019-11-05 2022-05-26 Dermira, Inc. ROR gamma T inhibitors and topical uses thereof
JP2023533123A (ja) * 2020-05-15 2023-08-02 シャンハイ ライテッド カンパニー リミテッド ＲＯＲγ調節剤として使用可能なアニリン化合物
CN113387842A (zh) * 2021-07-08 2021-09-14 成都泰和伟业生物科技有限公司 一种通过OTf胺化合成芳香伯胺的方法
CN120423960B (zh) * 2025-07-04 2025-09-12 山东第一医科大学(山东省医学科学院) 三氯化铁催化光引发硝基还原的方法

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001938A1 (en) 1990-07-20 1992-02-06 City Of Hope Derivatization of c-terminal proline
DE4211239C2 (de) 1992-04-03 1995-11-16 Max Planck Gesellschaft Arzneimittel gegen Herz-Kreislauf-Erkrankungen
JPH06145169A (ja) 1992-09-17 1994-05-24 Nippon Soda Co Ltd 新規な含窒素５員環化合物、その製造方法及び有害生物防除剤
JP3601898B2 (ja) 1996-02-14 2004-12-15 俊隆 鍋島 薬物依存形成抑制剤
CN1265673A (zh) * 1997-07-31 2000-09-06 伊兰药品公司 抑制由vla－4介导的白细胞粘着的二肽化合物
AU2337599A (en) 1998-01-23 1999-08-09 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
US6245746B1 (en) 1998-01-23 2001-06-12 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
JPH11292877A (ja) 1998-04-09 1999-10-26 Yamanouchi Pharmaceut Co Ltd １，４−ジ置換ピリドピラジン誘導体
JP2003526608A (ja) 1998-10-15 2003-09-09 バイオイメージ エイ／エス 再分布及び／又は標的化での干渉によって得られる特異的治療の介入
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
ES2313895T3 (es) 1999-06-14 2009-03-16 Henry Ford Health System Donadores de oxido nitrico para inducir neurogenesis.
US7655423B2 (en) 1999-06-14 2010-02-02 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
US7135498B1 (en) 1999-06-14 2006-11-14 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
FR2796947A1 (fr) 1999-07-30 2001-02-02 Aventis Pharma Sa Nouveaux derives 8-carbonyl chromanes, leur preparation et leur utilisation en therapeutique
WO2001032170A1 (en) 1999-09-13 2001-05-10 Swope David M Composition and method for decreasing neurologic symptomatology
AU2525701A (en) 1999-12-14 2001-06-25 Sanofi-Synthelabo Derivatives of quinazolinedione phthalimide, preparations thereof and their therapeutic uses
EP1237899A2 (en) 1999-12-16 2002-09-11 RiboTargets Limited Nucleic acid compounds and screening assays using the same
BR0107893A (pt) 2000-01-28 2002-11-05 Melacure Therapeutics Ab Agonistas e antagonistas de receptor de melanocortina
JP2004505054A (ja) 2000-08-01 2004-02-19 バイエル　アクチェンゲゼルシャフト 知覚を改善する医薬品としての選択的ｐｄｅ２インヒビター
US20020119978A1 (en) 2000-12-05 2002-08-29 Swope David M. Composition and method for decreasing neurologic symptomatology
DE10064105A1 (de) 2000-12-21 2002-06-27 Bayer Ag Neue Substituierte Imidazotriazinone
US6982274B2 (en) 2001-04-16 2006-01-03 Eisai Co., Ltd. 1H-indazole compound
IL162850A0 (en) 2002-01-04 2005-11-20 Ford Henry Health System Nitric oxide donors for treatment of disease and injury
DE60318267T2 (de) 2002-03-01 2008-12-11 Fujifilm Corp. Farbphotographisches lichtempfindliches Silberhalogenidmaterial
DE10224462A1 (de) 2002-06-03 2003-12-11 Bayer Ag Verwendung von cGMP stimulierenden Verbindungen
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
US7495016B2 (en) 2002-10-21 2009-02-24 Irm Llc Pyrrolidones with anti-HIV activity
DE60324449D1 (de) 2002-10-30 2008-12-11 Via Pharmaceuticals Inc Inhibitoren der phosphodiesterase der zyklischen n, und deren verwendung in therapie
AU2003276220A1 (en) 2002-11-13 2004-06-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 2a (pde2a)
AU2003296393A1 (en) 2002-12-30 2004-07-29 Eli Lilly And Company Factor xa inhibitors
US20070078144A1 (en) * 2003-01-29 2007-04-05 Stockwell Brent R Agents for treating neurodegenerative diseases
CA2517336A1 (en) 2003-03-04 2004-10-21 Altana Pharma Ag Purin-6-one-derivatives
US7250415B2 (en) 2003-06-04 2007-07-31 Bristol-Myers Squibb Company 1,1-Disubstitutedcycloalkyl-, glycinamidyl-, sulfonyl-amidino-, and tetrahydropyrimidinyl-containing diaminoalkyl, β-aminoacids, α-aminoacids and derivatives thereof as factor Xa inhibitors
CN1566099A (zh) 2003-06-13 2005-01-19 中国科学院上海药物研究所 异喹啉－1,3,4－三酮类化合物、制备方法及其用途
GB2404658A (en) 2003-08-07 2005-02-09 Bayer Ag Quinoxalinone derivatives and their use in the treatment of diseases
WO2005035534A1 (ja) 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. 複素ビシクロ環および複素トリシクロ環化合物およびその医薬
FR2860793A1 (fr) 2003-10-14 2005-04-15 Entomed Composes derives de norcantharidine, leurs procedes de preparation, les compositions les contenant et leurs utilisations
JP2005145840A (ja) 2003-11-12 2005-06-09 Nippon Soda Co Ltd 縮合ヘテロ環誘導体及び農園芸用殺菌剤
DK1697356T3 (da) 2003-12-16 2009-01-12 Pfizer Prod Inc Pyrido[2,3-d]pyrimidin-2,4-diaminer som PDE 2-inhibitorer
WO2005058892A1 (en) 2003-12-19 2005-06-30 Glaxo Group Limited Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors
CA2569402A1 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
WO2006015159A2 (en) 2004-07-29 2006-02-09 Merck & Co., Inc. Potassium channel inhibitors
WO2006064286A1 (en) 2004-12-13 2006-06-22 Medivir Uk Ltd Cathepsin s inhibitors
CA2591991C (en) 2005-01-05 2013-11-19 Altana Pharma Ag Triazolophthalazines
JP5240899B2 (ja) 2005-01-05 2013-07-17 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング トリアゾロフタラジン
WO2007094755A2 (en) 2005-02-04 2007-08-23 Massachusetts Institute Of Technology Compositions and methods for modulating cognitive function
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
WO2007020521A1 (en) 2005-08-16 2007-02-22 Pharmacia & Upjohn Company Llc Pyridoyrazinones as pde-5 inhibitors
JP2009535393A (ja) 2006-05-01 2009-10-01 ファイザー・プロダクツ・インク 置換２−アミノ縮合複素環式化合物
TW200815436A (en) 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
TW200817400A (en) 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
WO2007146230A2 (en) 2006-06-14 2007-12-21 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
WO2008044700A1 (en) 2006-10-11 2008-04-17 Takeda Pharmaceutical Company Limited GSK-3β INHIBITOR
DE102006048693A1 (de) 2006-10-14 2008-04-17 Bayer Healthcare Ag Inhibition der PDE2A
EP2120938A4 (en) 2006-12-20 2010-12-08 Merck Sharp & Dohme IMIDAZOPYRIDINE ANALOGUE AS CB2 RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES
WO2008121602A1 (en) 2007-03-29 2008-10-09 Smithkline Beecham Corporation Chemical compounds
GB0715103D0 (en) 2007-08-03 2007-09-12 Lectus Therapeutics Ltd Calcium ion channel modulators and uses thereof
WO2009026276A1 (en) 2007-08-22 2009-02-26 Irm Llc 5- (4- (haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
US7816540B2 (en) 2007-12-21 2010-10-19 Hoffmann-La Roche Inc. Carboxyl- or hydroxyl-substituted benzimidazole derivatives
CA2711995A1 (en) 2008-01-29 2009-08-06 F. Hoffmann-La Roche Ag Novel n-(2-amino-phenyl)-amide derivatives
CN102026961B (zh) 2008-05-14 2014-04-09 安斯泰来制药株式会社 酰胺化合物
AU2009248231A1 (en) 2008-05-16 2009-11-19 F. Hoffmann-La Roche Ag Novel N-(2-amino-phenyl)-acrylamides
US20110130365A1 (en) 2008-07-29 2011-06-02 Benbow John W Fluorinated Heteroaryls
NZ591366A (en) 2008-09-11 2012-05-25 Pfizer Heteroaryls amide derivatives and their use as glucokinase activators
US20100120762A1 (en) 2008-11-07 2010-05-13 Wyeth Triazine derivatives as inhibitors of phosphodiesterases
WO2010054260A1 (en) 2008-11-07 2010-05-14 Biotie Therapies Gmbh Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases
CA2751695C (en) 2009-02-06 2017-11-28 Nippon Shinyaku Co., Ltd. Aminopyrazine derivatives and medicines
EP2401275B1 (en) 2009-02-24 2013-07-24 Respiratorius AB Naphthyridine derivatives having bronchodilating activity
AR077033A1 (es) 2009-06-11 2011-07-27 Hoffmann La Roche Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas
US8691827B2 (en) 2009-08-17 2014-04-08 Merck Sharp & Dohme Corp. Amino tetrahydro-pyridopyrimidine PDE10 inhibitors
WO2011044157A1 (en) 2009-10-06 2011-04-14 Biogen Idec Ma Inc. Heterocyclic compounds useful as pdk1 inhibitors
CN102725291B (zh) 2009-10-29 2016-12-21 西特里斯药业公司 作为沉默调节蛋白调节剂的双环吡啶和相关的类似物
WO2012027965A1 (en) * 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
US20130184462A1 (en) 2010-09-30 2013-07-18 Council Of Scientific & Industrial Research Method for predicting and modeling anti-psychotic activity using virtual screening model
WO2012051036A1 (en) 2010-10-11 2012-04-19 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
WO2012064744A2 (en) 2010-11-08 2012-05-18 Lycera Corporation Tetrahydroquinoline and related bicyclic compounds for inhibition of rorϒ activity and the treatment of disease
US9265735B2 (en) 2010-11-30 2016-02-23 New York University Methods for screening to identify therapeutic agents for Alzheimer's disease and use thereof
BR112013015397A2 (pt) 2010-12-23 2016-09-20 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
WO2012100734A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Compounds useful as retinoid-related orphan receptor gamma modulators
PE20141637A1 (es) 2011-04-28 2014-11-20 Japan Tobacco Inc Compuesto de amida y aplicacion farmaceutica para el mismo
EP2716642B1 (en) 2011-05-30 2016-07-20 Astellas Pharma Inc. Imidazopyridine compound
EP2723747A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
EP2736330A4 (en) * 2011-07-29 2015-05-27 Tempero Pharmaceuticals Inc COMPOUNDS AND METHODS
US9156837B2 (en) 2011-07-29 2015-10-13 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP2759533B1 (en) 2011-09-22 2017-08-02 Takeda Pharmaceutical Company Limited Condensed heterocyclic compound
EP2766345B1 (en) 2011-10-14 2016-03-16 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2013064231A1 (en) * 2011-10-31 2013-05-10 Phenex Pharmaceuticals Ag SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3)
PH12014500988A1 (en) 2011-11-03 2014-06-09 Theravance Inc Rod -like hepatitis c virus inhibitors containing the fragement {2- [4- (bi phenyl -4 - yl) - 1h - imidazo - 2 - yl] pyrrolidine - 1 - carbonlymethyl} amine
DE102011085937B4 (de) 2011-11-08 2017-06-01 Airbus Operations Gmbh Leichtbaustruktur, insbesondere Flugzeugprimärstruktur oder untergeordnete Baugruppe, sowie Verfahren zu deren Herstellung
WO2013100027A1 (ja) 2011-12-28 2013-07-04 武田薬品工業株式会社 複素環化合物
WO2013146963A1 (ja) 2012-03-28 2013-10-03 武田薬品工業株式会社 複素環化合物
JP6157455B2 (ja) 2012-04-25 2017-07-05 武田薬品工業株式会社 含窒素複素環化合物
US9365530B2 (en) * 2012-05-07 2016-06-14 The University Of North Carolina At Chapel Hill Direct anti-markovnikov addition of acids to alkenes
US9527841B2 (en) 2012-07-13 2016-12-27 Takeda Pharmaceutical Company Limited Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors
WO2014142255A1 (ja) 2013-03-14 2014-09-18 武田薬品工業株式会社 複素環化合物
JP6427491B2 (ja) 2013-07-03 2018-11-21 武田薬品工業株式会社 複素環化合物
JP6411342B2 (ja) 2013-07-03 2018-10-24 武田薬品工業株式会社 アミド化合物
WO2015012328A1 (ja) 2013-07-24 2015-01-29 武田薬品工業株式会社 複素環化合物
WO2015016206A1 (ja) 2013-07-30 2015-02-05 武田薬品工業株式会社 複素環化合物
CN106795118B (zh) * 2014-07-01 2019-10-08 武田药品工业株式会社 杂环化合物和它们作为类视黄醇相关的孤儿受体(ror)gamma-t抑制剂的用途

Also Published As

Publication number Publication date
WO2015002231A1 (ja) 2015-01-08
EP3018126A1 (en) 2016-05-11
US10053468B2 (en) 2018-08-21
US20180319812A1 (en) 2018-11-08
JPWO2015002231A1 (ja) 2017-02-23
JP6427491B2 (ja) 2018-11-21
TW201602105A (zh) 2016-01-16
EP3018126A4 (en) 2016-12-07
US20170050974A1 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
AR098909A1 (es) Compuesto heterocíclico
AR109788A1 (es) Compuestos de benzo[b]tiofeno como agonistas de sting
AR111241A1 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
PE20160608A1 (es) Compuestos de quinolina selectivamente sustituida
AR104025A1 (es) Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas
AR089807A1 (es) Compuestos de imidazopirrolidinona
AR098492A1 (es) Derivados de purina
AR092742A1 (es) Piridinonas antifibroticas
AR111689A1 (es) Tienopiridinas y benzotiofenos útiles como inhibidores de irak4
AR103252A1 (es) Compuestos de quinazolina
AR100154A1 (es) Compuesto heterocíclico que contiene nitrógeno
AR095311A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
AR089865A1 (es) Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio
AR098721A1 (es) Inhibidores de biarilo de tirosina quinasa de bruton
AR091285A1 (es) Inhibidores de bromodominio y sus usos
ES2682398T3 (es) Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
AR094557A1 (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn
AR110282A1 (es) Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
AR103232A1 (es) ANTAGONISTAS DE TGFbR
AR094496A1 (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
AR100418A1 (es) Compuestos y composiciones para inducir condrogénesis
AR113886A1 (es) Derivados de indol macrocíclicos
AR092288A1 (es) Ligandos del receptor ep1
AR099933A1 (es) Derivados heterocíclicos de piridina agonistas de cb2
PE20221732A1 (es) Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano

Legal Events

Date Code Title Description
FB Suspension of granting procedure